Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017–7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 01:31pm CET

Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017–7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene’s management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company’s web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
03/23ARENA PHARMACEUTICALS : Pharma recovers from weight-loss failure
03/23CELGENE : Prothena Announces Global Neuroscience Research & Development Collabor..
03/22AGIOS PHARMACEUTICALS : Announces First Patient Dosed with MAT2A Inhibitor AG-27..
03/22ARENA PHARMACEUTICALS : Pharma recovers from weight-loss failure
03/22CELGENE : Prothena, Celgene ink neuro R&D pact potentially worth $2B+
03/22CELGENE : bucks trend to strengthen neuroscience pipeline
03/22CELGENE : pursues neuro breakthrough with $150m Prosena deal
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
03/21CELGENE : gets options to Prothena's tau, TDP-43 antibodies
More news
News from SeekingAlpha
03/22Incyte Is Worth $80 Even Without Epacadostat 
03/21FDA OKs Sun Pharma's Ilumya for plaque psoriasis 
03/21Premarket analyst action - healthcare 
03/21Geron's Imetelstat Hits A Grand Slam, But The Rally Is Just Beginning 
03/20CELGENE : A High-Growth Stock Trading At A Cheap Price 
Financials ($)
Sales 2018 14 804 M
EBIT 2018 8 491 M
Net income 2018 5 280 M
Debt 2018 274 M
Yield 2018 -
P/E ratio 2018 12,46
P/E ratio 2019 10,43
EV / Sales 2018 4,34x
EV / Sales 2019 3,47x
Capitalization 63 920 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 117 $
Spread / Average Target 38%
EPS Revisions
Mark J. Alles Chairman & Chief Executive Officer
Scott Andrew Smith President & Chief Operating Officer
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-8.64%207 583
PFIZER-1.71%205 314
ROCHE HOLDING LTD.-12.37%196 669
MERCK AND COMPANY-5.08%144 004